Q1AR2中英文对照.docx

Q1AR2中英文对照.docx

《Q1AR2中英文对照.docx》由会员分享，可在线阅读，更多相关《Q1AR2中英文对照.docx（38页珍藏版）》请在冰豆网上搜索。

Q1AR2中英文对照

人用药品注册技术要求国际协调会

ICH三方指导文件

新原料药和制剂的稳定性试验Q1A（R2）

现第四版

2003年2月6日制定

Q1A（R2）

文件历程

原编码

历史

日期

新编码

2005年11月

Q1

在第二阶段被指导委员会批准并公开发布征求意见

1992年9月16日

Q1

Q1A

在第四阶段被指导委员会批准并推荐给ICH三方当局征求意见。

Q1A从命名为Q1A

1993年10月27日

Q1A

Q1A（R）

第一次修订文本得到指导委员会批准并公开发布征求指导意见

1999年10月7日

Q1A（R1）

Q1A（R）

在第四阶段第一版被指导委员会批准并推荐给ICH三方当局征求意见。

2000年11月8日

Q1A（R1）

现第四版

Q1A（R2）

第四阶段第二版直接被指导委员会批准，没有公开发布征求意见。

此文本包含了因采纳Q1F（Ⅲ和Ⅳ气候带注册申请的稳定性数据包）所引起的改变，并推荐给ICH三方当局采纳。

2003年2月6日

Q1A（R2）

新原料药和制剂的稳定性试验Q1A（R）修订说明

本修订的目的为了明确由于采用了ICHQ1F“在气候带Ⅲ和Ⅳ注册申请的稳定性数据包”而使Q1A（R）而产生的变更。

这些变更如下：

1.在下面章节中将中间储存条件从温度30℃±2℃/相对湿度60%±5%修改为温度30℃±2℃/相对湿度65%±5%：

2.1.7.1原料药-储存条件-一般情况

2.2.7.1制剂-储存条件-一般情况

2.2.7.3在半渗透性容器中包装的制剂

3术语-“中间试验”

2.在下面章节中可以使用温度30℃±2℃/相对湿度65%±5%替代温度25℃±2℃/相对湿度60%±5%作为长期稳定性试验的条件：

2.1.7.1原料药-储存条件-一般情况

2.2.7.1制剂-储存条件-一般情况

3.在温度25℃±2℃/相对湿度40%±5%的基础上增加了温度30℃±2℃/相对湿度35%±5%作为长期稳定性试验条件，并且在后面的章节中包括了失水比率相关举例的相关情况：

2.2.7.3在半透性容器中包装的制剂

在试验阶段中间将中间将储存条件从温度30℃±2℃/相对湿度60%±5%调整为温度30℃±2℃/相对湿度65%±5%是可以的，但相应的储存条件和调整的日期要在注册申报资料中清楚地说明和列出。

如果适用的话建议ICH三方在公布和执行此修订指南三年后，注册申请资料中完整的试验能够包含在中间储存条件，即温度30℃±2℃/相对湿度65%±5%下的实验资料。

STABILITYTESTINGOFNEWDRUGSUBSTANCESANDPRODUCTS

1.INTRODUCTION

1.1.ObjectivesoftheGuideline

ThefollowingguidelineisarevisedversionoftheICHQ1AguidelineanddefinesthestabilitydatapackageforanewdrugsubstanceordrugproductthatissufficientforaregistrationapplicationwithinthethreeregionsoftheEC,Japan,andtheUnitedStates.Itdoesnotseeknecessarilytocoverthetestingforregistrationinorexporttootherareasoftheworld.

Theguidelineseekstoexemplifythecorestabilitydatapackagefornewdrugsubstancesandproducts,butleavessufficientflexibilitytoencompassthevarietyofdifferentpracticalsituationsthatmaybeencounteredduetospecificscientificconsiderationsandcharacteristicsofthematerialsbeingevaluated.Alternativeapproachescanbeusedwhentherearescientificallyjustifiablereasons.

1.2.ScopeoftheGuideline

Theguidelineaddressestheinformationtobesubmittedinregistrationapplicationsfornewmolecularentitiesandassociateddrugproducts.Thisguidelinedoesnotcurrentlyseektocovertheinformationtobesubmittedforabbreviatedorabridgedapplications,variations,clinicaltrialapplications,etc.

Specificdetailsofthesamplingandtestingforparticulardosageformsintheirproposedcontainerclosuresarenotcoveredinthisguideline.

Furtherguidanceonnewdosageformsandonbiotechnological/biologicalproductscanbefoundinICHguidelinesQ1CandQ5C,respectively.

1.3.GeneralPrinciples

Thepurposeofstabilitytestingistoprovideevidenceonhowthequalityofadrugsubstanceordrugproductvarieswithtimeundertheinfluenceofavarietyofenvironmentalfactorssuchastemperature,humidity,andlight,andtoestablishare-testperiodforthedrugsubstanceorashelflifeforthedrugproductandrecommendedstorageconditions.

ThechoiceoftestconditionsdefinedinthisguidelineisbasedonananalysisoftheeffectsofclimaticconditionsinthethreeregionsoftheEC,JapanandtheUnitedStates.Themeankinetictemperatureinanypartoftheworldcanbederivedfromclimaticdata,andtheworldcanbedividedintofourclimaticzones,I-IV.ThisguidelineaddressesclimaticzonesIandII.TheprinciplehasbeenestablishedthatstabilityinformationgeneratedinanyoneofthethreeregionsoftheEC,JapanandtheUnitedStateswouldbemutuallyacceptabletotheothertworegions,providedtheinformationisconsistentwiththisguidelineandthelabelingisinaccordwithnational/regionalrequirements.

2.GUIDELINES

2.1.DrugSubstance

2.1.1.General

Informationonthestabilityofthedrugsubstanceisanintegralpartofthesystematicapproachtostabilityevaluation.

2.1.2.StressTesting

Stresstestingofthedrugsubstancecanhelpidentifythelikelydegradationproducts,whichcaninturnhelpestablishthedegradationpathwaysandtheintrinsicstabilityofthemoleculeandvalidatethestabilityindicatingpoweroftheanalyticalproceduresused.Thenatureofthestresstestingwilldependontheindividualdrugsubstanceandthetypeofdrugproductinvolved.

Stresstestingislikelytobecarriedoutonasinglebatchofthedrugsubstance.Itshouldincludetheeffectoftemperatures（in10°Cincrements（e.g.,50°C,60°C,etc.）abovethatforacceleratedtesting）,humidity（e.g.,75%RHorgreater）whereappropriate,oxidation,andphotolysisonthedrugsubstance.ThetestingshouldalsoevaluatethesusceptibilityofthedrugsubstancetohydrolysisacrossawiderangeofpHvalueswheninsolutionorsuspension.Photostabilitytestingshouldbeanintegralpartofstresstesting.ThestandardconditionsforphotostabilitytestingaredescribedinICHQ1B.

Examiningdegradationproductsunderstressconditionsisusefulinestablishingdegradationpathwaysanddevelopingandvalidatingsuitableanalyticalprocedures.However,itmaynotbenecessarytoexaminespecificallyforcertaindegradationproductsifithasbeendemonstratedthattheyarenotformedunderacceleratedorlongtermstorageconditions.

Resultsfromthesestudieswillformanintegralpartoftheinformationprovidedtoregulatoryauthorities.

2.1.3.SelectionofBatches

Datafromformalstabilitystudiesshouldbeprovidedonatleastthreeprimarybatchesofthedrugsubstance.Thebatchesshouldbemanufacturedtoaminimumofpilotscalebythesamesyntheticrouteas,andusingamethodofmanufactureandprocedurethatsimulatesthefinalprocesstobeusedfor,productionbatches.Theoverallqualityofthebatchesofdrugsubstanceplacedonformalstabilitystudiesshouldberepresentativeofthequalityofthematerialtobemadeonaproductionscale.

Othersupportingdatacanbeprovided.

2.1.4.ContainerClosureSystem

Thestabilitystudiesshouldbeconductedonthedrugsubstancepackagedinacontainerclosuresystemthatisthesameasorsimulatesthepackagingproposedforstorageanddistribution.

2.1.5.Specification

Specification,whichisalistoftests,referencetoanalyticalprocedures,andproposedacceptancecriteria,isaddressedinICHQ6AandQ6B.Inaddition,specificationfordegradationproductsinadrugsubstanceisdiscussedinQ3A.

Stabilitystudiesshouldincludetestingofthoseattributesofthedrugsubstancethataresusceptibletochangeduringstorageandarelikelytoinfluencequality,safety,and/orefficacy.Thetestingshouldcover,asappropriate,thephysical,chemical,biological,andmicrobiologicalattributes.Validatedstability-indicatinganalyticalproceduresshouldbeapplied.Whetherandtowhatextentreplicationshouldbeperformedwilldependontheresultsfromvalidationstudies.

2.1.6.TestingFrequency

Forlongtermstudies,frequencyoftestingshouldbesufficienttoestablishthestabilityprothedrugsubstance.Fordrugsubstanceswithaproposedre-testperiodofatleast12months,thefrequencyoftestingatthelongtermstorageconditionshouldnormallybeevery3monthsoverthefirstyear,every6monthsoverthesecondyear,andannuallythereafterthroughtheproposedre-testperiod.

Attheacceleratedstoragecondition,aminimumofthreetimepoints,includingtheinitialandfinaltimepoints（e.g.,0,3,and6months）,froma6-monthstudyisrecommended.Whereanexpectation（basedondevelopmentexperience）existsthatresultsfromacceleratedstudiesarelikelytoapproachsignificantchangecriteria,increasedtestingshouldbeconductedeitherbyaddingsamplesatthefinaltimepointorbyincludingafourthtimepointinthestudydesign.

Whentestingattheintermediatestorageconditioniscalledforasaresultofsignificantchangeattheacceleratedstoragecondition,aminimumoffourtimepoints,includingtheinitialandfinaltimepoints（e.g.,0,6,9,12months）,froma12-monthstudyisrecommended.

2.1.7.StorageConditions

Ingeneral,adrugsubstanceshouldbeevaluatedunderstorageconditions（withappropriatetolerances）thattestitsthermalstabilityand,ifapplicable,itssensitivitytomoisture.Thestorageconditionsandthelengthsofstudieschosenshouldbesufficienttocoverstorage,shipment,andsubsequentuse.

Thelongtermtestingshouldcoveraminimumof12months’durationonatleastthreeprimarybatchesatthetimeofsubmissionandshouldbecontinuedforaperiodoftimesufficienttocovertheproposedre-testperiod.Additionaldataaccumulatedduringtheassessmentperiodoftheregistrationapplicationshouldbesubmittedtotheauthoritiesifrequested.Datafromtheacceleratedstorageconditionand,ifappropriate,fromtheintermediatestorageconditioncanbeusedtoevaluatetheeffectofshorttermexcursionsoutsidethelabelstorageconditions（suchasmightoccurduringshipping）.

Longterm,accelerated,and,whereappropriate,intermediatestorageconditionsfordrugsubstancesaredetailedinthesectionsbelow.Thegeneralcaseappliesifthedrugsubstanceisnotspecificallycoveredbyasubsequentsection.Alternativestorageconditionscanbeusedifjustified.

2.1.7.1.Generalcase

Study

Storagecondition

Minimumtimeperiodcoveredbydataatsubmission

Longterm*

25°C±2°C/60%RH±5%RHor30°C±2°C/65%RH±5%RH

12months

Intermediate**

30°C±2°C/65%RH±5%RH

6months

Accelerated

40°C±2°C/75%RH±5%RH

6months

*Itisuptotheapplicanttodecidewhetherlongtermstabilitystudiesareperformedat25±2°C/60%RH±5%RHor30°C±2°C/65%RH±5%RH.

**If30°C±2°C/65%RH±5%RHisthelong-termcondition,thereisnointermediatecondition.

Iflong-termstudiesareconductedat25°C±2°C/60%RH±